Optimizing antimetabolite-based chemotherapy for the treatment of childhood acute lymphoblastic leukaemia.
about
Model-Based Individualized Treatment of Chemotherapeutics: Bayesian Population Modeling and Dose OptimizationAcute lymphoblastic leukaemia: a model for the pharmacogenomics of cancer therapy.Value of intravenous 6-mercaptopurine during continuation treatment in childhood acute lymphoblastic leukemia and non-Hodgkin's lymphoma: final results of a randomized phase III trial (58881) of the EORTC CLG.
P2860
Optimizing antimetabolite-based chemotherapy for the treatment of childhood acute lymphoblastic leukaemia.
description
2000 nî lūn-bûn
@nan
2000 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Optimizing antimetabolite-base ...... acute lymphoblastic leukaemia.
@ast
Optimizing antimetabolite-base ...... acute lymphoblastic leukaemia.
@en
type
label
Optimizing antimetabolite-base ...... acute lymphoblastic leukaemia.
@ast
Optimizing antimetabolite-base ...... acute lymphoblastic leukaemia.
@en
prefLabel
Optimizing antimetabolite-base ...... acute lymphoblastic leukaemia.
@ast
Optimizing antimetabolite-base ...... acute lymphoblastic leukaemia.
@en
P2093
P2860
P1476
Optimizing antimetabolite-base ...... acute lymphoblastic leukaemia.
@en
P2093
P2860
P356
10.1046/J.1365-2141.2000.02028.X
P407
P577
2000-07-01T00:00:00Z